X
[{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Shares Preclinical Efficacy Data on Telotristat Ethyl\u2019s Antiproliferative Effects Against Various Cancer Cell Lines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"TerSera","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"$159.0 million","newsHeadline":"Lexicon Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For The Sale Of Xermelo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"$41.0 million","newsHeadline":"Lexicon Pharmaceuticals Reaches Agreements To Exchange Convertible Notes, Reduce Outstanding Indebtedness","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TerSera\u00ae Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo\u00ae (telotristat ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Telotristat Ethyl
Filters
Companies By Therapeutic Area
Details:
Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Lead Product(s):
Telotristat Ethyl
Therapeutic Area: Gastroenterology
Product Name: Xermelo
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 09, 2021
Details:
With this agreement including the repayment of Lexicon’s secured loan concurrent with the closing of its sale of XERMELO®, Lexicon will have reduced the principal amount of its outstanding debt, supporting advancement of its LX9211 neuropathic pain program and other trials.
Lead Product(s):
Telotristat Ethyl
Therapeutic Area: Gastroenterology
Product Name: Xermelo
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $62.5 million
Upfront Cash: $41.0 million
Deal Type: Agreement
September 23, 2020
Details:
As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.
Lead Product(s):
Telotristat Ethyl
Therapeutic Area: Oncology
Product Name: Xermelo
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
TerSera
Deal Size: $224.0 million
Upfront Cash: $159.0 million
Deal Type: Agreement
July 30, 2020
Details:
Lexicon Pharmaceutical to present four posters highlighting XERMELO at the virtual Cholangiocarcinoma Foundation Annual Conference. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor cells.
Lead Product(s):
Telotristat Ethyl
Therapeutic Area: Oncology
Product Name: Xermelo
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 20, 2020
Details:
Additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines were presented at the ASCO 2020 annual meeting.
Lead Product(s):
Telotristat Ethyl
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2020